PDGFRB and acute myeloid leukemia: Second‐generation FLT3 inhibitors include quizartinib (AC220; Daiichi Sankyo),15, 16 a highly selective inhibitor of FLT3‐ITD that does not inhibit FLT3‐TKD (D835 or F691) in patients,17 crenolanib besylate (CP‐868596; AROG Pharmaceuticals, LLC),18 which has FLT3‐ITD and FLT3‐TKD and PDGFR as targets, and the FLT3 and AXL inhibitor, gilteritinib (ASP2215, XOSPATA; Astellas Pharma US, Inc),19, 20 which was FDA‐approved for patients with relapsed or refractory AML with an identified FLT3 mutation, based on results of the ADMIRAL trial (NCT02421939).